Articles related to BREAST CANCER

The recent FDA approval of Lumicell’s breast cancer imaging system introduces a novel intraoperative tool that significantly enhances the precision of tumor resections, potentially reducing the need for subsequent corrective surgeries.

In an era where personalized treatment is paramount, the evolving landscape of axillary management in breast cancer stresses the shift towards minimizing surgical intervention while ensuring optimal patient outcomes.

This study reinforces the noninferiority of sentinel node biopsy in patients with clinically node-negative breast cancer, offering a potential paradigm shift in surgical decision-making and patient care.

The combination of ribociclib and a nonsteroidal aromatase inhibitor was associated with a notable improvement in invasive disease–free survival rates among early-stage, HR-positive, HER2-negative breast cancer patients, highlighting a significant advancement in the therapeutic landscape of this common malignancy.

Explore groundbreaking trials from SABCS 2023, revealing the potential of sacituzumab govitecan and datopotamab deruxtecan in enhancing treatment paradigms for metastatic breast cancer, spotlighting pivotal advancements in antibody-drug conjugate therapy.

Explore the transformative potential of antibody-drug conjugates (ADCs) in cancer therapy, offering targeted treatments with reduced side effects. Recent approvals and ongoing trials signify a significant shift towards precision medicine in oncology.